DPD status and fluoropyrimidines-based treatment: high activity matters too

by Chamorey, Emmanuel, Francois, Eric, Etienne, Marie-Christine, Ferrero, Jean-Marc, Peyrade, Frederic, Barranger, Emmanuel, Bozec, Alexandre, Largillier, Rémy, Cassuto, Ophelie, Viotti, Julien, Schiappa, Renaud, Milano, Gérard
Published in BMC Cancer (2020)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

by Cassuto, Ophélie, Dufies, Maeva, Jacquel, Arnaud, Robert, Guillaume, Ginet, Clémence, Dubois, Alix, Hamouda, Amine, Puissant, Alexandre, Luciano, Fredéric, Karsenti, Jean-Michel, Legros, Laurence, Cassuto, Jill Patrice, Lenain, Pascal, Auberger, Patrick
Published 2012

Nous devons respecter le schéma vaccinal anti-SARS-CoV-2 sans décalage chez les patients atteints de cancer sous traitement

by Barrière, Jérôme, Audigier-Valette, Clarisse, Borchiellini, Delphine, Hoch, Benjamin, Castelnau, Olivier, Francois, Eric, Gastaud, Lauris, Skaf, Richard, Berdah, Jean-François, Marie, Wislez, Lescaut, Willy, Peyrade, Frédéric, Cluzeau, Thomas, Cassuto, Ophélie, Carles, Michel
Published in Bull Cancer (2021)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

by Dufies, Maeva, Giuliano, Sandy, Viotti, Julien, Borchiellini, Delphine, Cooley, Linsay S, Ambrosetti, Damien, Guyot, Mélanie, Ndiaye, Papa Diogop, Parola, Julien, Claren, Audrey, Schiappa, Renaud, Gal, Jocelyn, Frangeul, Antoine, Jacquel, Arnaud, Cassuto, Ophélie, Grépin, Renaud, Auberger, Patrick, Bikfalvi, Andréas, Milano, Gérard, Escudier, Bernard, Rioux-Leclercq, Nathalie, Porta, Camillo, Negrier, Sylvie, Chamorey, Emmanuel, Ferrero, Jean-Marc, Pagès, Gilles
Published in Br J Cancer (2017)